Managing the Acute Side Effects of Concurrent Chemoradiation
Track
:
PRES
Program Code:
PRES300
Date:
Sunday, September 21, 2008
Time:
1:00 PM to 2:30 PM
EST
Duration:
1800 Minutes
Location:
BCC Grand Ballroom
SPEAKER(S):
Click the plus sign to see more detailed information
about each speaker.
David Brizel, Professor, Duke University Medical Center
Dr. Drake Brizels clinical interests include head and neck cancer, non-melanoma skin cancer, targeted therapy, and tumor physiology. His research interests include the treatment of head and neck cancer has constituted both my principal clinical focus and the framework for my research efforts since my arrival at Duke in 1987. I led an in house randomized trial which was one of the first to demonstrate that concurrent chemoradiation was more efficacious than radiotherapy alone for locally advanced head and neck cancer. Reduction of treatment induced morbidity has been a major interest of mine. I served as the principal investigator of the pivotal randomized trial of amifostine in head and neck cancer. This study established proof of priniciple for the feasibility of pharmacologic radioprotection. The FDA approved this drug for protection against radiation induced xerostomia based on this trial. Presently, I am involved in preclinical and clinical studies that are evaluating the potential role of keratinocyte growth factor for protection against radiation induced mucositis and pneumonitis. One of these is a multi-center clinical trial that is evaluating the ability of keratinocyte growth factor to diminish the severity of mouth and throat soreness that develops during chemoradiation for head and neck cancer. I have served as co-Principal Investigator of a multinational randomized trial that tested the benefit of adding the hypoxic cell cytotoxin, tirapazamine, to concurrent chemoradiation in advanced head and neck cancer. I am conducting a unique clinical trial that combines both EGFR blockade (Tarceva) and VEGF blockade (Avastin) simultaneously with our standard regimen of hyperfractionated irradiation and concurrent cisplatin in advanced head and neck cancer.
Christopher Crane, Associate Professor, Chief, GI Section, M.D. Anderson Cancer Center
Dr. Christopher Crane is an Associate Professor in the Department of Radiation Oncology at the University of Texas MD Anderson Cancer Center where he has been Program Director of Gastrointestinal Radiation Oncology at since 2001. He also serves as the Program Director of the Residency and Fellowship Training Programs. He has been invited to speak widely on gastrointestinal topics both nationally and internatinally and authored or coauthored over 75 manuscripts as well as 35 text book chapters and 30 invited publications focusing on gastrointestinal malignancies. His primary research focus has been the combination of novel chemotherapeutic agents with radiation therapy in pancreatic and rectal cancers in prospective phase I and phase II trials as well as teaching the multidisciplinary management and supportive care of patients with gastrointestinal malignancies.
Eighteen years of Oncology nursing experience. I was the Primary nurse for the Head and Neck Patients in Radiation Oncology at Duke University Hospital for the past 18 months. I just recently accepted a new position in clinical research in radiation oncology and continue to work closely with our Head and Neck Patients who are on clinical trials.
Poster Presentation at 2008 Oncology Nursing Society Conference: DEVELOPMENT OF A MULTI-DISCIPLINARY PATIENT CARE TEAM; A COLLABORATIVE APPROACH TO OPTIMIZE CARE FOR PATIENTS WITH HEAD AND NECK CANCER.
Maria Petzel, Senior Clinical Dietitian, M.D. Anderson Cancer Center
Maria Petzel works exclusively in the field of oncology nutrition. She is a leader in her field recently gaining the qualification of Certified Specialist in Oncology Nutrition. Petzel has contributed to several publications including book chapters, peer reviewed journals, and patient newsletters regarding nutrition and cancer.
Andy Trotti, MD
Professor and Director of Clinical Trials for Radiation Oncology
Moffitt Cancer Center
Tampa, Florida
Dr. Trotti is a Professor and Director of Clinical Trials in Radiation Oncology at the Moffitt Cancer Center and is recognized for his expertise in Head and Neck (H&N) cancer and in the adverse effects of cancer treatment. His interests include improving the efficacy of radiotherapy in head and neck cancer clinical trials through integration of fractionation, cytotoxic agents and biologics. He currently serves as the Co-Chair of the NCI H&N Steering Committee responsible for development and approval of Phase II and III trials. Dr. Trotti is also Co-Chair of the Head and Neck Committee for the Radiation Therapy Oncology Group (RTOG), serves on the AJCC Executive Committee and the NCCN H&N Committee. In June 2008 Dr. Trotti delivered the honorary annual Wharton Lecture at Princess Margaret Hospital on the “Evolution of Adverse Event Reporting in Oncology.” He has co-authored several landmark RTOG studies of fractionation and organ preservation and is recognized for his work in developing the NCI adverse event (AE) grading dictionaries (NCI-CTCAE) now widely used in oncology. Dr. Trotti is currently leading initiatives to develop AE reporting standards and new methods to summarize, analyze and display adverse event data.